Background: Despite intensive research it is unknown if treatment with antipsychotic drugs contributes to the reduced life-expectancy observed in patients with schizophrenia and other severe mental disorders. As randomized controlled trials (RCT) are considered the best evidence to examine causal relationship, we aimed to analyze mortality related to antipsychotics based on all placebo-controlled RCTs conducted so far. Methods: We evaluated mortality in pair-wise meta-analysis of RCTs comparing second-generation-antipsychotics versus placebo across all diagnostic fields. Information about deaths was extracted from summary data of clinical trials as identified by two searches (last 01/28/2017) in several electronic databases. Furthermore, manufacturing companies and regulatory authorities were contacted, and their websites were searched for trial reports and supplemental information about fatal events. We examined mortality due to any reason (primary outcome), due to natural causes, suicide, and other unnatural causes. We synthesized the results with odds ratios (OR) in a common-effect meta-analysis. We addressed the effects of age, diagnostic field, gender, study duration, antipsychotic drug used, drug dose and polypharmacy with subgroup-and meta-regression-analyses. We used the GRADE framework to evaluate the confidence in the evidence. Results: We included 596 randomized trials that reported 207 deaths in 53804 patients on placebo (0.38%) and 99 deaths in 31184 patients on drug (0.32%). There was no evidence of significant difference between antipsychotics and placebo regarding mortality due to any reason (OR 1.19; 95% CI 0.93, 1.53), natural causes (OR 1.29; 95% CI 0.85, 1.94), suicide (OR 1.15; 95% CI 0.47, 2.81) and other unnatural causes (OR 1.55; 95% CI 0.66, 3.63). The number-needed-to-harm for all-cause mortality was 6 more deaths in 10 000 drug-treated patients compared to placebo, with a 95% CI ranging from 2 helped to 14 harmed. Most deaths occurred in patients with dementia and these patients also had the highest drug-related mortality in subgroup analysis (OR 1.56; 95% CI 1 .10, 2.21). The OR for patients with schizophrenia (based on 32807 patients) was 0.69 (95 CI 0.35, 1,35). Discussion: We found no evidence of increased mortality related to treatment with second generation antipsychotic drugs, neither in the overall sample nor in the subgroup of patients with schizophrenia. Results of subgroup analyses indicated however that mortality of patients with dementia might be increased when they are exposed to antipsychotics. Strength of the analysis are the use of data from RCTs and the comprehensive search, which aimed to identify all placebo-controlled RCTs of second generation antipsychotics conducted so far. Limitations of our analysis are the remaining imprecision of the results with a 95% confidence interval including the risk of more than 1 patient harmed in 1000 patients treated with antipsychotics. Moreover, we could only address short-term effects leading to death, but not long-term effects -such as induction of metabolic syndrome -which also contribute to the increased mortality over the whole life-span.
T7. PHARMACOGENETIC OF TARDIVE
Background: Tardive dyskinesia (TD) is a motor side effect that may arise after long-term treatment of antipsychotic drugs. Its etiology is not well understood, but a number of risk factors have been associated with TD. TD occurrence appears to be familial, thus suggesting a genetic component. We previously reported on an association between the SLC18A2 gene that codes for the vesicular monoamine transporter 2 (VMAT2) that packages monoamines including dopamine from the cytoplasm into synaptic vesicles (Zai et al, 2013) . In the present study, we examined the dopamine transporter gene SLC6A3 by itself and in conjunction with SLC18A2 for possible association with TD. Methods: We genotyped and analyzed the variable-number tandem repeat (VNTR) polymorphism in the 3' untranslated region of the SLC6A3 gene in our European sample of 187 schizophrenia/schizoaffective disorder patients assessed for TD occurrence based on the Abnormal Involuntary Movement Scale (AIMS). We also explored the interaction between the VNTR and the TD-associated SLC18A2 marker rs363224. Results: Our preliminary analysis did not show the SLC6A3 VNTR to be associated with TD occurrence or severity. There also appeared to be no significant interaction between SLC6A3 VNTR and SLC18A2 rs363224 in TD occurrence or severity (p>0.05). Discussion: Our findings did not support a major role of the dopamine transporter gene in TD risk or severity, but we will examine additional putative functional markers in this gene. 
T8. NEUROLOGICAL SOFT SIGNS (NSS) IN

Methods:
A search of studies which had assessed NSS in adult schizophrenia patients and included at least one follow-up examination was undertaken. Studies which had been published between January 1966 and June 2017 and listed in relevant databases were included. Due to the fact, that ongoing brain maturation lasts until adulthood and is paralleled by a loss of those NSS which are present in childhood, studies on teenagers were excluded. Results: Twenty-nine follow-up studies were identified which overall used well-known instruments for the investigation of NSS. Patients were at different disease stages. All expressed abnormally increased NSS, however to different extents. An NSS reduction during the course was detected in most first episode patients and those with a remitting course whereas chronically ill patients exhibited stable or increasing NSS scores. The change over time could for the most part be attributed to changes in the motor system subscales and to a lesser amount to sensory integration scales. As opposed to the earlier notion that medication evokes or worsens NSS, studies largely agreed on a positive interrelation between medication response and improvement of NSS. The type of antipsychotic was of small importance and when side-effects were commented on there was a weak relationship with NSS. On the other hand, studies gave some hints at relationships between NSS and symptoms, i.e. negative and cognitive symptoms. Discussion: The reviewed studies confirmed the presence of abnormal, i.e. elevated NSS in patients diagnosed with schizophrenia. Studies disagreed on the amount of abnormalities in NSS. However, subgroups emerged with
